Skip to content

LEXINGTON, Mass., June 26, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that members of the Company’s leadership team will be featured speakers at the 4thMicrobiome Movement – Drug Development Summit which is being held today through June 28, 2019 in Boston.

Kaleido will participate in the following sessions at the Summit on June 27, 2019, which is also World Microbiome Day:

Opening Panel: Microbiome Industry Leaders Panel Discussion
Speaker: Alison Lawton, President & Chief Executive Officer
Time: 8:30 am ET

Presentation: A Chemistry-Driven Approach to Leveraging the Potential of the Microbiome Organ to Treat Disease and Improve Human Health
Presenter: Katharine Knobil, M.D., Chief Medical Officer and Head of Research & Development
Time: 4:10 pm ET
Kaleido intends to post Dr. Knobil’s presentation to the Events and Presentations page of the Company’s website following the event.

Panel Discussion: Building Clear Regulatory Guidelines for Microbiome-based Therapeutics
Speaker: Susan Stewart, Senior Vice President, Regulatory Affairs & Quality
Time: 6:15 pm ET

World Microbiome Day is dedicated to raising awareness of the diverse world of microbes, and this year’s theme is focused on the growing public health threat presented by the rise in antibiotic resistance. Kaleido is developing KB109, a Microbiome Metabolic Therapy (MMT™) candidate to address infections caused by multi-drug resistant (MDR) bacteria. The Company is initiating a clinical study of KB109 in patients colonized with vancomycin-resistant Enterococcus (VRE), extended-spectrum beta lactamase (ESBL)-producing Enterobacteriaceae, or carbapenem-resistant Enterobacteriaceae (CRE).

“As we continue to learn more about the role of the microbiome in health and disease, Kaleido, with our differentiated approach, is proud to be a part of the commitment to translating its promise into solutions for patients,” said Alison Lawton, President and Chief Executive Officer, Kaleido.

Click here for a video describing the role of the microbiome in health and disease and Kaleido’s differentiated approach.

About Kaleido Biosciences

Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the therapeutic potential of our MMT candidates and our strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar words and expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words or expressions.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to non-IND clinical studies of our MMT product candidates, such as KB109, including statements regarding the rapidity at which our human-centric discovery and development platform can advance our MMT product candidates, the clinical development and safety profile of our MMT candidates and their therapeutic potential, whether and when, if at all, our MMT candidates will receive approval form the U.S. Food and Drug Administration and for which, if any, indications, competition from other biotechnology companies, and other risks identified in our SEC filings, including our Quarterly Report on Form 10-Q for the first quarter of 2019, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

Press Contact
Amy Reilly